CGC · Canopy Growth Corporation

The thesis

Canopy Growth's shares closed at $0.67 on 28 October 2026, 65.0% below the 52-week high of $1.92, even after the DEA judge removed the main procedural threat to rescheduling on 22 October 2026. Two events settle the next step: the 5 November 2026 deadline for reply briefs in the rescheduling case and the second-quarter fiscal 2027 results, expected around 6 November 2026.

On 22 October 2026 Administrative Law Judge Derek Julius declined to reopen the hearing for new testimony and evidence. He admitted the Government Accountability Office (GAO) report to the record and set narrow briefing on its weight, according to NORML and Cannabis Business Times. Briefs from the DEA and seven opposing parties were due by 29 October 2026, with replies by 5 November 2026. The stay entered on 29 September 2026 expires when that schedule ends.

The shareholder side moved too. The meeting reconvened on 23 October 2026 and approved a share consolidation of between one-for-five and one-for-fifteen, with 121,567,723 votes for, 28,460,796 against and turnout of 36.60% of shares outstanding, as reported by MarketBeat and Stock Titan. The board decides whether and when to use it. The shares fell from $0.74 on 15 October 2026 to $0.67 on 28 October 2026 despite both pieces of news.

The narrative is maturing: the rescheduling story is well known, and the 22 October 2026 order cleared a delay risk without lifting the price. A Canadian licensed producer gets no Section 280E tax relief from a US reschedule, so the link to Canopy runs through sentiment and indirect US exposure via Canopy USA.

Bullish and bearish views on Canopy Growth Corporation

The bull case on Canopy Growth Corporation (CGC), in brief: The hearing will not reopen. The bear case: The price ignored good news.

Bull case

• The hearing will not reopen. The 22 October 2026 order denied opponents' request for new testimony and discovery (NORML; Cannabis Business Times). That removes the risk the prior note flagged, a recommendation pushed into 2027.
• Medical revenue is growing. The 7 August 2026 report showed Canadian medical revenue of C$25.8 million, up 22% year over year, and international cannabis revenue of C$9.6 million, up 10%.
• Margins and losses improved. Adjusted gross margin was 31% for the quarter ended 30 June 2026, against 25% a year earlier. The adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) loss was C$3.2 million, on revenue of C$81.2 million, up 13%.
• The shares are deeply oversold. The 14-day relative strength index (RSI) was 20.2 on 28 October 2026, and the three-month price change was -26.8%.

Bear case

• The price ignored good news. The shares closed at $0.74 on 15 October 2026 and $0.67 on 28 October 2026, after the 22 October 2026 order and the 23 October 2026 vote.
• Cash burn exceeds the adjusted loss. Free cash outflow was C$25.7 million for the quarter ended 30 June 2026, and total debt was C$240.2 million at that date.
• The ruling is still not a rescheduling. The judge's recommendation has no binding deadline, and the GAO briefing runs to at least 5 November 2026. Any recommendation then goes on to the DEA's final decision.
• Consolidation does not change the business. The vote drew 36.60% turnout, just above the 33 1/3% quorum. Canopy completed a one-for-ten consolidation after a Nasdaq deficiency letter dated 11 July 2023, and the shares kept falling afterwards in the years since.

Price setup

The last adjusted close is $0.67 on 28 October 2026. The 14-day RSI is 20.2, an extreme run of down days. The prior note's $0.66 invalidation level sits 1.5% below that close, so the shares are close to it.

Closes have stepped down: $1.00 on 28 August 2026, $0.88 on 2 October 2026, $0.74 on 15 October 2026 and $0.67 on 28 October 2026. The $1.00 close of 28 August 2026 is the nearest overhead price. Nasdaq's $1.00 minimum bid requirement is why the consolidation authority exists.

Crowding evidence is thin on the upside. No new SEC filings or insider transactions are in the news flow since 15 October 2026. The results date is the one near-term event that could move the shares sharply either way. Sources differ on how long the consolidation authority lasts: post-meeting coverage says 12 months, while the proxy statement of 17 August 2026 said until 25 September 2027. The Form 8-K is the authoritative document.

Catalysts, next 30 days

• ~6 November 2026, est.: Second-quarter fiscal 2027 results. Last year's second-quarter report came on 7 November 2025 and the first-quarter report on 7 August 2026. Canopy had not announced the date in sources found by 29 October 2026.
• No date: The board's choice of consolidation ratio and timing, if it acts.

Elapsed catalysts

• 29 October 2026: Opening briefs due from the DEA and seven opposing parties on the weight of the GAO report (NORML). (passed 8d ago)
• 5 November 2026: Reply briefs due. The stay expires at the end of this schedule, after which Julius can resume the recommendation. (passed 1d ago)

What would change the view

The case would break if the judge's briefing leads to a recommendation against Schedule III, or if the November results show cash outflow at or above the C$25.7 million of the prior quarter alongside weaker medical or international revenue. A daily close below $0.60 would also break it, as a decline through the recent run of lower closes.

The case would strengthen if the results show free cash outflow below C$25.7 million, Canadian medical revenue above C$25.8 million and international revenue above C$9.6 million, and the shares reclaim the $0.74 close of 15 October 2026.

What it trades with

Canopy trades with US-listed cannabis shares on federal rescheduling headlines, and its moves on the 22 October 2026 order were small against the multi-week decline. It also trades on Toronto under WEED, so USD/CAD moves can separate the two prices. Its debt and cash burn make it more sensitive to financing and share-count news than to sector policy alone.